A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
about
Middle East respiratory syndrome: obstacles and prospects for vaccine developmentAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesMultimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNAGutless adenovirus: last-generation adenovirus for gene therapyA novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicityAdenoviral vectors as novel vaccines for influenza.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.HIV-1 vaccine development after STEP.The influence of innate and pre-existing immunity on adenovirus therapyImmunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityReplicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.The influence of delivery vectors on HIV vaccine efficacyPotent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein DHeterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsModification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responsesNovel adenovirus vector-based vaccines for HIV-1.The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.Cofactors that may influence vaccine responses.Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challengeVaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques.Challenges in the development of an HIV-1 vaccine.Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Genetic medicine strategies to protect against bioterrorism.Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vectorQuantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsHuman immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypesRobust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
P2860
Q27013314-9629A969-0528-4704-97CF-6A5D2CB0116CQ27013568-39E82358-06C1-45C5-BEEE-E79E67F0A990Q27472925-E5A86ADD-6FBC-4A9E-8C46-1657D627759AQ27472927-87E1CCFE-A3D0-42B4-925D-5197ADDBFC1FQ28251922-03EB377B-AB4C-4FEE-AF8D-7438CA95FEFFQ28277560-4B00A0CF-2721-4E68-A279-C3B396E1EAFBQ28727030-837E773F-74FA-4BF3-A4BE-2FF28F6FF331Q30370445-D8EF6619-CBA9-44B5-9395-7381D09600D4Q30378897-826AC45D-24A2-4A0E-BDD6-933DDB745728Q33642318-5BE52277-85AE-4FE6-989E-7E960D58E120Q33655401-F4BD791F-EEA2-411F-A3C5-BC1A78729283Q33908767-9DE743E6-CEC3-4E54-A11C-E5302ED75F23Q33911986-D3CDC43A-B3A0-43FC-924F-0186FA9ED8F1Q34033557-E7726977-3AC6-4668-A72A-5AABCC04E0D5Q34077543-2D916D84-6645-464A-974B-F374754A4593Q34081164-CADEF740-41E4-4A61-ADBB-29A75E50A6E2Q34178208-D2898E53-E051-42AD-8B0C-9017DF6FE75BQ34189966-47A82949-DBB4-4F4B-AF74-FB32BBBABD7FQ34204440-0210EE1A-59B6-4397-8FBF-0FDFC97BFCAFQ34229968-8688209D-7245-4619-BF36-7019D4111D5AQ34257640-C4FC07AE-A5CF-4859-9ACE-63D04AE06A7DQ34289823-B6407043-02FF-483D-B67C-5D49D5549D3FQ34297930-48B239EF-752A-48AF-BD73-6FDA8E7E2E08Q34301004-6A16D9EB-941C-46BF-9271-3BA2D8CCEBFBQ34383008-DB78D157-952C-4F12-B762-7F19039A7BB4Q34556871-0B0C134B-8CC5-4F58-B6DB-9ED160F1E8BEQ34657290-D7203809-549A-4E70-84A4-0F329251A60DQ34701517-079B9EBB-4CA2-43AE-8CE9-3990072CC973Q34767181-D967D667-EA0B-41C6-A258-9CE0237F436EQ35022798-E0EF6788-D824-429D-BFCB-A97B61C1EB77Q35069550-4323CA92-D876-4820-ACC9-F3C1C6AD8485Q35112755-46DD352B-EA9E-4194-A2AA-8341DCF43910Q35123692-33E3096D-0D32-4D13-A268-FB0F69C87F02Q35159523-38FE9792-1C89-4E6A-828E-5512693A0BA8Q35317858-7DD16C49-A1CC-45A5-B53C-7B4F3FCBA752Q35344875-AD5E9D47-40B4-4439-9E53-071DCE5A89ECQ35728235-4D94E0C2-F9B5-4EC1-A421-1BD26C76E26FQ35792153-64F0EC9B-552B-42B7-8581-04CBB397E7D7Q35826388-523FC8B1-C920-4A02-8FF4-23246C3784ABQ35857215-C5C3AD57-1247-4686-B7C2-578F24B2E1B2
P2860
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
@en
type
label
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
@en
prefLabel
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
@en
P2093
P1476
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
@en
P2093
Anthony P Wlazlo
Arturo Reyes-Sandoval
George N Pavlakis
Guang-Ping Gao
Hildegund C J Ertl
James M Wilson
Wynetta Giles-Davis
Zhi Q Xiang
P304
P356
10.4049/JIMMUNOL.170.3.1416
P407
P577
2003-02-01T00:00:00Z